Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04754802 | PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge | PHASE3 | COMPLETED | 224 | — | — | May 24, 2021 | Jun 22, 2022 | Sep 12, 2025 | 21 | United States |
The SUDS is a patient self-rated scale that is scored in the range of 0 to 100 (operationalized for participants in this study as 0=totally relaxed or no anxiety and 100=highest distress or anxiety ever felt
| Arm | Type | Description |
|---|---|---|
| PH94B | EXPERIMENTAL | PH94B Nasal Spray - single treatment with 3.2 micrograms PH94B |
| Placebo | EXPERIMENTAL | Placebo Nasal Spray - single treatment with placebo |
| Name | Type | Description |
|---|---|---|
| PH94B Nasal Spray | DRUG | Nasal spray delivered 20 minutes before the public speaking stressor |
| Placebo Nasal Spray | DRUG | Nasal spray delivered 20 minutes before the public speaking stressor |
Inclusion Criteria: 1. Written informed consent provided prior to conducting any study-specific assessment. 2. Male or female adult, 18 through 65 years of age, inclusive. 3. Current diagnosis of SAD as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, as confirmed ...